Quantcast

Latest squamous cell carcinoma Stories

2014-03-31 23:25:26

New research report “NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool” worked out by GBI Research is now available at MarketPublishers.com. According to the study, the APAC NSCLC market is predicted to post a 6.3% CAGR to amount to USD 2.9 billion by 2019. London, UK (PRWEB) March 31, 2014 As for 2012, the non-small cell lung cancer (NSCLC) market in the APAC region was evaluated...

2014-03-28 23:04:53

Markets Research Reports.biz added deep and professional market research reports on "NSCLC Therapeutics In Asia-Pacific Markets To 2019 - Personalized Therapies Focus On Untapped Segment Of Squamous Cell Carcinoma To Expand Treatment Pool" Market Analysis and Overview. Visit: http://www.marketresearchreports.biz/analysis-details/nsclc-therapeutics-in-asia-pacific-markets-to-2019-personalized-therapies-focus-on-untapped-segment-of-squamous-cell-carcinoma-to-expand-treatment-pool....

2014-03-20 16:26:44

Public Can Get Free Screenings During Oral Head and Neck Cancer Awareness Week®, April 20-26 NEW YORK, March 20, 2014 /PRNewswire/ -- A first-of-its-kind study shows that sore throat and neck mass are the most common initial symptoms of a form of oral, head and neck cancer that is rapidly increasing in incidence, oropharyngeal squamous cell carcinoma (OPSCC). The study, published online March 20, 2014 in JAMA Otolaryngology - Head & Neck Surgery, cites sore throat as the most...

2014-03-15 08:21:28

DALLAS, March 15, 2014 /PRNewswire/ -- ReportsnReports.com offers "Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability" and "NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool" research reports in its store. According to Epilepsy Therapeutics in Asia Pacific Markets to...

2014-03-05 08:30:26

Patient-friendly treatment helps minimize radiation exposure to healthy tissues LOS GATOS, Calif., March 5, 2014 /PRNewswire/ -- On January 14, a 67-year-old male patient received his final Esteya® electronic brachytherapy session to treat a squamous cell carcinoma on his right hand. He was the first patient in the United States to receive Esteya treatment, which was delivered at a Los Gatos, California clinic by Rakesh Patel, MD, Medical Director at The Targeted Radiation Institute...

2014-03-04 23:30:56

The Sensus Healthcare SRT-100™ is a non-invasive skin cancer treatment system. The SRT-100™ will provide the local patient community with the most effective, non-surgical and pain free therapy to treat non-melanoma skin cancers, such as Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC), which account for the vast majority of all skin cancers. Roslyn Heights, NY (PRWEB) March 04, 2014 Skin Cancer Radiotherapy Institute (SCRI) announced that they are the first medical...

2014-03-04 23:28:32

Treatments are Top Procedure in 2013 Rolling Meadows, IL (PRWEB) March 04, 2014 Not only are skin cancer treatments again the top procedure performed by American Society for Dermatologic Surgery members but the number of cases continues to rise, according to a recent ASDS survey. ASDS members performed more than 3 million skin cancer treatments in 2013, an increase of 13 percent from 2012, according to the 2013 ASDS Survey on Dermatologic Procedures released last month. Skin cancer is...

2014-02-26 08:29:54

LOS ANGELES, Feb. 26, 2014 /PRNewswire/ -- Los Angeles dermatologist, Dr. Peyman Ghasri, offers a variety of treatments for skin cancer. Skin cancer is the most common form of cancer in the United States today and can cause significant pain, disfigurement and death. Early identification and treatment of cancer is generally associated with more positive outcomes. About Dr. Peyman Ghasri, Skin Doctor Los Angeles Dr. Ghasri is a premier dermatologist. He graduated magna cum laude from...

2014-02-19 08:31:13

-- Ramucirumab Improved Survival in Second-Line Study of Patients with Non-Small Cell Lung Cancer -- INDIANAPOLIS, Feb. 19, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the REVEL trial, a global Phase III study of ramucirumab in combination with chemotherapy in patients with second-line non-small cell lung cancer (NSCLC), showed a statistically significant improvement in the primary endpoint of overall survival in the ramucirumab-plus-docetaxel arm...

2014-02-04 12:27:40

Program goal is improved understanding of individual risk for recurrence in patients diagnosed with early stage melanoma FRIENDSWOOD, Texas, Feb. 4, 2014 /PRNewswire/ -- Castle Biosciences Inc., a leading developer of diagnostic and prognostic tests for rare cancers, today announced the launch of an educational program dedicated to the information needs of Stage I and II skin (cutaneous) melanoma patients and their caregivers. The program kicks off with the launch of an animated...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.